BPTH Stock Price, Bio-Path Holdings Inc Quote, Chart

Market Summary

USD2.68+0.04

Market Closed

1.52%

BPTH Stock Price

View Fullscreen

BPTH RSI Chart

BPTH Valuation

Market Cap

1.8M

Price/Earnings (Trailing)

-0.11

EV/EBITDA

-0.59

Price/Free Cashflow

-0.16

MarketCap/EBT

-0.77

BPTH Price/Sales (Trailing)

BPTH Profitability

Return on Equity

-3.6K%

Return on Assets

-499.32%

Free Cashflow Yield

-634.08%

BPTH Fundamentals

BPTH Earnings

Earnings (TTM)

-16.1M

Earnings Growth (Yr)

14.98%

Earnings Growth (Qtr)

-5.41%

Breaking Down BPTH Revenue

Last 7 days

-37.5%

Last 30 days

-33.7%

Last 90 days

470.2%

Trailing 12 Months

107.9%

How does BPTH drawdown profile look like?

BPTH Financial Health

Current Ratio

1.6

BPTH Investor Care

Shares Dilution (1Y)

55.18%

Diluted EPS (TTM)

-33.65

Tracking the Latest Insider Buys and Sells of Bio-Path Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 18, 2019	armistice capital, llc	sold	-	-	-	-
Jan 18, 2019	armistice capital, llc	sold	-171,643	2.6629	-64,457	-

Which funds bought or sold BPTH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Allworth Financial LP	sold off	-100	-70.00	-	-%
Apr 25, 2024	Allworth Financial LP	new	-	5.00	5.00	-%
Apr 23, 2024	Global Retirement Partners, LLC	sold off	-100	-32.00	-	-%
Apr 23, 2024	Global Retirement Partners, LLC	new	-	16.00	16.00	-%
Apr 03, 2024	Strategic Advocates LLC	sold off	-100	-16,260	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	77.52	68,740	125,023	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	11,202	11,202	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-6,871	-	-%
Feb 14, 2024	Walleye Capital LLC	sold off	-100	-77,418	-	-%

Are Funds Buying or Selling BPTH?

Are funds buying BPTH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BPTH

No. of Funds

Unveiling Bio-Path Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	intracoastal capital, llc	7.1%	53,700	SC 13G
Feb 02, 2024	hudson bay capital management lp	5.43%	709,616	SC 13G
Feb 14, 2020	sassicaia capital advisers llc	0%	0	SC 13G/A
Feb 14, 2020	anson funds management lp	-	0	SC 13G/A
Feb 10, 2020	cvi investments, inc.	4.0%	152,328	SC 13G/A
Jan 15, 2020	empery asset management, lp	0.14%	5,148	SC 13G/A
Jan 06, 2020	sabby management, llc	0.45%	16,708	SC 13G/A
Dec 02, 2019	cvi investments, inc.	5.5%	202,020	SC 13G
Dec 02, 2019	intracoastal capital, llc	4.3%	163,932	SC 13G
Nov 27, 2019	armistice capital, llc	3.9%	151,515	SC 13G

Recent SEC filings of Bio-Path Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	D	D
Apr 24, 2024	S-1	Initial Public Offering
Apr 19, 2024	424B5	Prospectus Filed
Apr 19, 2024	424B5	Prospectus Filed
Apr 19, 2024	8-K	Current Report
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 05, 2024	D	D
Apr 04, 2024	424B5	Prospectus Filed

Peers (Alternatives to Bio-Path Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Bio-Path Holdings Inc News

Latest updates

Bio-Path Holdings Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-35.9%	3.00	5.00	7.00	11.00	16.00	19.00	21.00	24.00	27.00	31.00	31.00	33.00	16.00	15.00	18.00	20.00	23.00	18.00	19.00	21.00	3.00
Current Assets	-36.7%	3.00	5.00	6.00	11.00	16.00	18.00	21.00	24.00	26.00	30.00	31.00	33.00	16.00	14.00	17.00	19.00	22.00	17.00	19.00	21.00	2.00
Cash Equivalents	-55.3%	1.00	2.00	3.00	7.00	10.00	14.00	17.00	21.00	24.00	27.00	28.00	31.00	14.00	12.00	14.00	18.00	20.00	15.00	17.00	19.00	1.00
Net PPE	-17.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	11.3%	3.00	2.00	1.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00	2.00	1.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00
Current Liabilities	40.5%	2.00	1.00	1.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00
Shareholder's Equity	-82.5%	0.00	3.00	5.00	9.00	14.00	16.00	20.00	22.00	25.00	29.00	30.00	31.00	15.00	13.00	16.00	18.00	21.00	16.00	18.00	20.00	1.00
Retained Earnings	-3.2%	-107	-104	-101	-96.80	-91.53	-87.56	-84.03	-81.02	-77.66	-73.54	-71.48	-69.67	-67.22	-64.67	-61.70	-59.66	-56.34	-53.95	-51.71	-49.25	-47.74
Additional Paid-In Capital	1.2%	108	107	106	106	106	104	104	103	103	103	101	101	82.00	78.00	78.00	78.00	77.00	70.00	70.00	69.00	49.00
Accumulated Depreciation	1.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Shares Outstanding	-100.0%	-	11.00	8.00	8.00	-	7.00	7.00	7.00	7.00	7.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	14.00	-	-	-	28.00	-	-	-	46.00	-	-	-	18.00	-	-	-	37.00	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	34.8%	-1,814	-2,781	-3,287	-3,653	-5,000	-3,374	-4,203	-2,526	-2,801	-2,891	-2,653	-1,572	-2,592	-2,353	-3,480	-2,535	-2,245	-1,893	-2,215	-2,008	-1,283
Share Based Compensation	1.1%	180	178	170	206	209	212	213	217	230	262	189	140	145	143	119	170	162	184	181	157	138
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-23.00	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	-	514	-	-	-	-	-	-	-	-3.00	1,399	-	18,610	4,289	-	-	-	7,289	169	45.00	20,280	1.00

BPTH Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 11,608	$ 9,165
General and administrative	4,235	4,736
Total operating expenses	15,843	13,901
Net operating loss	(15,843)	(13,901)
Other income
Interest income	36	33
Change in fair value of warrant liability	(271)
Total other income	(235)	33
Net loss	$ (16,078)	$ (13,868)
Net Loss Per Share, Basic
Net loss per share, basic	$ (33.63)	$ (38.12)
Weighted average number of common shares outstanding, basic	478	364
Net Loss Per Share, Diluted
Net loss per share, diluted	$ (33.63)	$ (38.12)
Weighted average number of common shares outstanding, diluted	478	364

BPTH Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash	$ 1,052	$ 10,384
Prepaid drug product	632	3,587
Other current assets	1,358	1,644
Total current assets	3,042	15,615
Fixed assets
Furniture, fixtures & equipment	1,120	1,120
Less accumulated depreciation	(1,044)	(962)
Fixed assets, net	76	158
Right of use operating assets	102	198
Total Assets	3,220	15,971
Current liabilities
Accounts payable	457	667
Accrued expenses	1,346	909
Current portion of lease liabilities	103	108
Total current liabilities	1,906	1,684
Warrant liability	863
Noncurrent lease liabilities	10	113
Total Liabilities	2,779	1,797
Shareholders' equity
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value; 200,000 shares authorized; 618 and 398 shares issued and outstanding, respectively	1	1
Additional paid in capital	108,047	105,702
Accumulated deficit	(107,607)	(91,529)
Total shareholders' equity	441	14,174
Total Liabilities & Shareholders' Equity	$ 3,220	$ 15,971

About Bio-Path Holdings Inc

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

CEO	Mr. Peter H. Nielsen MBA
WEBSITE	biopathholdings.com
INDUSTRY	Biotechnology
EMPLOYEES	10

Bio-Path Holdings Inc Frequently Asked Questions

What is the ticker symbol for Bio-Path Holdings Inc? What does BPTH stand for in stocks?

BPTH is the stock ticker symbol of Bio-Path Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Path Holdings Inc (BPTH)?

As of Fri Apr 26 2024, market cap of Bio-Path Holdings Inc is 1.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BPTH stock?

You can check BPTH's fair value in chart for subscribers.

What is the fair value of BPTH stock?

You can check BPTH's fair value in chart for subscribers. The fair value of Bio-Path Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Path Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BPTH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Path Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether BPTH is over valued or under valued. Whether Bio-Path Holdings Inc is cheap or expensive depends on the assumptions which impact Bio-Path Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BPTH.

What is 5 year return on Bio-Path Holdings Inc's stock?

In the past 10 years, Bio-Path Holdings Inc has provided -0.403 (multiply by 100 for percentage) rate of return.